<DOC>
	<DOCNO>NCT01792323</DOCNO>
	<brief_summary>To cover meal-related insulin requirement , insulin pump allow insulin deliver high rate short period time ( bolus delivery ) . The length period ( bolus duration ) usually depend chosen bolus size use insulin pump model . This study evaluate impact different bolus duration ( i.e. , duration commonly employ commercially available insulin pump : 2 40 second deliver 1 Unit insulin ) pharmacokinetic pharmacodynamic property rapid-acting insulin analogue . Objective : To evaluate type 1 diabetic patient pharmacodynamics pharmacokinetics rapid-acting insulin ( insulin lispro ) administer subcutaneous bolus different bolus duration . Study design : Single-center , randomize , control , two-arm cross-over intervention study Population : Twenty type 1 diabetic subject Intervention : The investigational treatment subcutaneous administration insulin lispro either one bolus 15 IU period 30 one bolus 15 IU period 10 min . Plasma sample assess pharmacodynamic pharmacokinetic property take 8-hour clamp experiment . Patients undergo investigational treatment randomize order ; two clamp visit wash-out period 5-21 day . Main study endpoint : Time maximum glucose infusion rate</brief_summary>
	<brief_title>Absorption Insulin Following Subcutaneous Bolus Administration With Different Bolus Durations</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Informed consent obtain advised nature study Male female age 1860 year ( inclusive ) Type 1 diabetes treat multiple daily insulin injection continuous subcutaneous insulin infusion 12 month Fasting Cpeptide &lt; 0.3nmol/L Body mass index 20.030.0 kg/mÂ² ( inclusive ) HbA1c &lt; 10 % Female childbearing potential pregnant , breastfeed intend become pregnant use adequate contraceptive method Skin pathology condition prohibit needle insertion/insulin administration judge investigator History bleed disorder Current participation another clinical study Use insulin lispro &gt; 2 week Significant acute chronic illness might interfere subject safety integrity result judge investigator Smoker ( define &gt; 5 cigarettes/d ) Lipodystrophy Current treatment systemic ( oral i.v . ) corticosteroid , monoamine oxidase ( MAO ) inhibitor , nonselective betablockers , growth hormone , herbal product nonroutine vitamin . Furthermore , thyroid hormone allow unless use stable past 3 month Significant history alcoholism drug abuse positive result urine drug/alcohol screen Study Day Strenuous exercise within last 24 hour prior clamp visit Nonfasting ( i.e . consumption food beverage , water , later 22:00 hour even visit ) except slight intake rapidly absorbable carbohydrate necessary order prevent hypoglycaemia Injection longacting insulin ( e.g . insulin glargine insulin detemir ) later 12:00 hour ( noon ) , 2 day clamp visit Injection NPH insulin intermediateacting insulin product later 12:00 hour ( noon ) day clamp visit Injection short act insulin ( aspart , lispro , glulisine ) 6 IU human insulin 22:00 hour 03:00 hour night clamp visit Injection insulin later 03:00 hour night clamp visit Infusion insulin later 03:00 hour night clamp visit subject use continuous subcutaneous insulin infusion ( CSII ) Positive result alcohol breath test Any medical condition , opinion Investigator , could interfere insulin pharmacokinetics and/or glucose metabolism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>insulin pump therapy</keyword>
	<keyword>insulin bolus</keyword>
	<keyword>rapid act insulin</keyword>
	<keyword>insulin lispro</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>glucose clamp</keyword>
</DOC>